Receptor News and Research

RSS

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors.

4 Apr 2014

Infants show unique physiological, behavioral responses to pleasant touch, says study

Infants show unique physiological and behavioral responses to pleasant touch, which may help to cement the bonds between child and parent and promote early social and physiological development, according to research published in Psychological Science, a journal of the Association for Psychological Science.

3 Apr 2014

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.

2 Apr 2014

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity.

1 Apr 2014

Wen Dan Tang significantly reduces insomnia-related anxiety

Ghrelin, a brain-gut peptide that induces anxiety and other abnormal emotions, contributes to the effects of insomnia on emotional behavior. In contrast, the traditional Chinese Medicine remedy Wen Dan Tang reduces insomnia-related anxiety, which may perhaps correspond to changes in the brain-gut axis.

1 Apr 2014

NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.

1 Apr 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Einstein faculty members present recent research at AACR Annual Meeting

From uncovering the role nerve cells play in metastasis to identifying new cancer-causing genes, researchers at Albert Einstein College of Medicine of Yeshiva University made notable advances in the understanding and potential treatment of cancer during the past year.

29 Mar 2014

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

A Canadian institution that annually recognizes seminal medical discoveries selected cancer immunotherapy leader Jim Allison, Ph.D., chair and professor of Immunology at The University of Texas MD Anderson Cancer Center, for one of its 2014 Canada Gairdner International Awards.

29 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

New drug multiplies analgesic effect of opioids without increasing constipation

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

27 Mar 2014

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Transforming growth factor-beta (TGF-β) type II receptor (TβRII) levels are extremely low in the brain tissue of patients with Alzheimer's disease.

27 Mar 2014

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.

27 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

Receptor News and Research

Sanford-Burnham to present new cancer research data at AACR 2014

Infants show unique physiological, behavioral responses to pleasant touch, says study

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Wen Dan Tang significantly reduces insomnia-related anxiety

NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Einstein faculty members present recent research at AACR Annual Meeting

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

New drug multiplies analgesic effect of opioids without increasing constipation

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

New technology gives tool to examine membrane proteins in natural environment of human cell

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Nasal spray holds promise as potential alternative therapeutic approach for depression

CSP analogues may attenuate S. pneumoniae virulence, resistance

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News